emfizatamab   Click here for help

GtoPdb Ligand ID: 12177

Synonyms: GNC 038 | GNC-038 | GNC038
Compound class: Antibody
Comment: Emfizatamab (GNC-038) is a humanized immunotherapeutic monoclonal antibody that is engineered to engage 4 molecular targets (tetra-specific), to provide immunostimulatory and antineoplastic activities as an approach to treat B cell malignancies. The protein targets are CD19, CD3e, PD-L1 and 4-1BB. Emfizatamab is designed to crosslink CD19-expressing tumour B cells with cytotoxic T lymphocytes (via CD3e binding). It also targets PD-L1 on the tumour cells (preventing interaction with the inhibitory T cell checkpoint protein PD-1), and engagement of 4-1BB (TNFRSF9) acts as a co-stimulatory signal on T cells that is proposed to enhance anti-tumour activity. Likely one of the so-called 'guidance and navigation control (GNC)' proteins that are claimed in Sichuan Baili Pharmaceutical/Systimmune patent US20210024630A1 [1].
Classification Click here for help
Compound class Antibody
International Nonproprietary Names Click here for help
INN number INN
12023 emfizatamab
Synonyms Click here for help
GNC 038 | GNC-038 | GNC038
Database Links Click here for help
Specialist databases
IMGT/mAb-DB 1248
Other databases
GtoPdb PubChem SID 472319299
Search PubMed clinical trials emfizatamab
Search PubMed titles emfizatamab
Search PubMed titles/abstracts emfizatamab